A Preliminary Investigation of the Mechanism of P2RX3-
mediated Central Sensitization in Migraine

Wenxin Bao; Chenyang Li; Li Chen*; Jiajun Yang*

doi:10.18686/pmr.v2i2.4432

A Preliminary Investigation of the Mechanism of P2RX3- mediated Central Sensitization in Migraine

Wenxin Bao, Chenyang Li, Li Chen*, Jiajun Yang*

Abstract

Migraine is a prevalent neurological disorder affecting approximately 15% of the global population, but its pathogenesis has not yet
been elucidated. Migraine pathogenesis is importantly associated with central sensitization, and P2RX3 plays a key role in central sensitization. In this study, we investigated the mechanism of P2RX3 in central sensitization of migraine, with the aim of providing a new theoretical
basis for migraine treatment.

Keywords

Migraine; Central sensitization; P2RX3; CGRP; cAMP/MAPK/CREB

Full Text:

PDF

Included Database

References

[1] ZUPAN M, ZALETEL M, VISOCNIK D, et al. Calcitonin gene-related peptide-induced hemodynamic changes in migraine with and

without aura [J]. Acta Neurol Scand, 2021, 144(6): 616-22.

[2] GAETE P S, LILLO M A, PUEBLA M, et al. CGRP signalling inhibits NO production through pannexin-1 channel activation in endothelial cells [J]. Sci Rep, 2019, 9(1): 7932.

[3] CERUTI S, VILLA G, FUMAGALLI M, et al. Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: implications for basic mechanisms of migraine pain [J]. J Neurosci, 2011, 31(10): 3638-49.

[4] GINIATULLIN R, NISTRI A, FABBRETTI E. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF [J]. Mol Neurobiol, 2008, 37(1): 83-90.

[5] RUSSO A F, HAY D L. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond [J]. Physiol Rev, 2023, 103(2): 1565-644.

[6] ZHANG Z, WINBORN C S, MARQUEZ DE PRADO B, et al. Sensitization of calcitonin gene-related peptide receptors by receptor

activity-modifying protein-1 in the trigeminal ganglion [J]. J Neurosci, 2007, 27(10): 2693-703.

[7] HAANES K A, LABASTIDA-RAMIREZ A, BLIXT F W, et al. Exploration of purinergic receptors as potential anti-migraine targets

using established pre-clinical migraine models [J]. Cephalalgia, 2019, 39(11): 1421-34.

[8] PENG L, AGOGO G O, GUO J, et al. Substance P and fibrotic diseases [J]. Neuropeptides, 2019, 76: 101941.

[9] HOLZER P. Neurogenic vasodilatation and plasma leakage in the skin [J]. Gen Pharmacol, 1998, 30(1): 5-11.

[10] CORRIGAN F, VINK R, TURNER R J. Inflammation in acute CNS injury: a focus on the role of substance P [J]. Br J Pharmacol, 2016,

173(4): 703-15.

DOI: http://dx.doi.org/10.18686/pmr.v2i2.4432

Refbacks

There are currently no refbacks.